Oncology Drug Advisory Committee
 | This article includes a list of references, related reading, or external links, but its sources remain unclear because it lacks inline citations. (June 2019) |
The Oncologic Drugs Advisory Committee (ODAC) receives requests for technical and clinical evaluation of new drugs by the U.S. Food and Drug Administration (FDA). The committee, consisting of members from academic and clinical oncology biostatistics, the general public, and the pharmaceutical industry, makes non-binding recommendations to both the CDER and CBER divisions of the FDA about the advisability of approving new medications to treat cancer.
References[edit]
- Oncologic Drugs Advisory Committee, official webpage: https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/default.htm
External links[edit]
- FDA Advisory Committees Calendar (including ODAC): https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm
 | This oncology article is a stub. You can help Wikipedia by expanding it. |
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |